dc.contributor.advisorRojas-Villarraga, Adriana 
dc.creatorTorres Garrido, Alba Luz 
dc.creatorVargas-Zambrano, Juan-Camilo 
dc.date.accessioned2014-11-18T13:18:04Z
dc.date.available2014-11-18T13:18:04Z
dc.date.created2014-08-01
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/9026
dc.descriptionIntroducción: Las vacunas clásicamente han representado un método económico y eficaz para el control y prevención de múltiples enfermedades infecciosas. En los últimos años se han introducido nuevas vacunas contra neumococo a precios elevados, y los diferentes análisis económicos a nivel mundial de estas vacunas no muestran tendencias. El objetivo de este trabajo era resumir la evidencia existente a través de los diferentes estudios económicos evaluando las dos vacunas de segunda generación contra neumococo en la población a riesgo. Metodología: En este trabajo se realizo una revisión sistemática de la literatura en 8 bases de datos localizadas en diferentes partes del mundo y también que tuvieran literatura gris. Los artículos fueron inicialmente evaluados acorde a su titulo y resumen, posteriormente los elegidos se analizaron en su totalidad. Resultados: Se encontraron 404 artículos, de los cuales 20 fueron incluidos en el análisis final. Se encontró que la mayoría de los estudios se realizaron en áreas donde la enfermedad tiene una carga baja, como es Norte América y Europa, mientras que en los lugares del mundo donde la carga es mas alta, se realizaron pocos estudios. De igual manera se observo que la mayoría de los estudios mostraron por los menos ser costo efectivos respecto a la no vacunación, y en su totalidad las dos vacunas de segunda generación mostraron costo efectividad respecto a la vacunación con PCV-7. Los resultados de los estudios son muy heterogéneos, hasta dentro del mismo país, señalando la necesidad de guías para la conducción de este tipo de estudios. De igual manera, la mayoría de los estudios fueron financiados por farmacéuticas, mientras en un numero muy reducido por entes gubernamentales. Conclusiones: La mayoría de los estudios económicos sobre las vacunas de segunda generación contra neumococo han sido realizados en países con un alto índice de desarrollo económico y patrocinados por farmacéuticas. Dado que la mayoría de la carga de la enfermedad se encuentran en regiones con un menor nivel de desarrollo económico se deberían realizar mas en estas zonas. De igual manera, al ser la vacunación un asunto de salud publica y con un importante impacto económico los gobiernos deberían estar mas involucrados en los mismos.
dc.description.abstractIntroduction: An easy and effective method for control and prevention of multiple infectious diseases has been massive vaccination. Lately, two new conjugate vaccines against pneumococcus appeared at high prices, and economical analysis do not show a tendency towards the use of this vaccine. The objective of this work was to collect and analyze available information regarding economical evaluations of second-generation pneumococcal conjugate vaccines in risk population. Methodology: Information was systematically gathered through a systematic review of the literature. Eight different databases, located in different countries, and some containing grey literature were used to look for the articles. Initially articles were assessed according to their title and abstract. Afterwards, selected articles were completely read and analyzed for final inclusion. Results: This work was systematic review, in which 404 articles were found and 20 were included in the final analysis. It was found that most of the studies were done in North America and Europe, while countries with the highest burden of the disease (Africa and South East Asia), only few studies were done. Moreover, it was seen that most of the studies showed that the two new vaccines were at least cost effective respect to the use of PCV-7. The results were very heterogeneous, and even in the same country. This shows the need of guidelines for this type of studies. Finally, most of the studies were sponsor by pharmaceutical companies, while just a reduced number were by governmental funds. Conclusions: The vast majority of studies were done in countries with a high index of development and sponsored by pharmaceutical companies. Due to the fact that the burden of pneumococcal infection is located in other regions, associated with countries with a lower development index, more studies are needed in these locations. Likewise, as this is a public health issue, governments should be more strongly involved, conducting and publishing their own economical analyses.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.subjectvacunas conjugadas
dc.subjectNeumococo
dc.subjectFarmacoeconomia
dc.subject.ddc614.4
dc.titleAnálisis económico de las vacunas 10-valente y 13-valente contra neumococo: revisión sistemática
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Epidemiología (en Convenio con el CES)
dc.publisher.departmentFacultad de medicina
dc.subject.keywordpharmacoeconomics
dc.subject.keywordpneumococcus
dc.subject.keywordConjugate vaccines
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsVacuna cuadrivalente
dc.subject.decsEpidemiología
dc.subject.decsbacterias estreptocócicas
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationKlimek J, Cavallito C, Bailey J. Induced resistance of Staphylococcis aureus to antibiotics. J Bacteriol. 1946;51:580.
dc.source.bibliographicCitationBreman JG, Arita I. The Confirmation and Maintenance of Smallpox Eradication. N Engl J Med [Internet]. 1980;303(22):1263–73. Available from: http://www.nejm.org/doi/full/10.1056/NEJM198011273032204
dc.source.bibliographicCitationAl Ghamdi SS, Fallatah HI, Fetyani DM, Al-Mughales JA, Gelaidan AT. Long-term efficacy of the hepatitis B Vaccine in a high-risk group. J Med Virol [Internet]. 2013;85(9):1518–22. Available from: http://dx.doi.org/10.1002/jmv.23658
dc.source.bibliographicCitationDrummond MF, O’Brien BJ, Torrance GW, Stoddart GL. Methods for the economic evaluation of health care programmes. The journal of mental health policy and economics. 1987.
dc.source.bibliographicCitationWHO. WHO guide for standardization of economic evaluations of immunization programmes WHO guide for standardization of economic evaluations of immunization programmes Immunization , Vaccines and Biologicals. 1st ed. World Health. Geneve: World Health Organization; 2008.
dc.source.bibliographicCitationZhou F, Santoli J, ML M, Al E. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the united states, 2001. Arch Pediatr Adolesc Med [Internet]. 2005 Dec 1;159(12):1136–44. Available from: http://dx.doi.org/10.1001/archpedi.159.12.1136
dc.source.bibliographicCitationAsh SY, Sheffield JVL. Pneumococcus. Med Clin North Am [Internet]. 2013 Jul [cited 2013 Aug 11];97(4):647–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23809718
dc.source.bibliographicCitationTan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev [Internet]. 2012 Jul [cited 2013 Sep 21];25(3):409–19. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3416489&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationPeters TR, Abramson JS. ( Pneumococcus ) [Internet]. Nineteenth. Nelson Textbook of Pediatrics, 19/e. Elsevier Inc.; Available from: http://dx.doi.org/10.1016/B978-1-4377-0755-7.00175-5
dc.source.bibliographicCitationDockrell DH, Whyte MKB, Mitchell TJ. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest [Internet]. 2012 Aug [cited 2013 Sep 21];142(2):482–91. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3425340&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationDonkor ES. Understanding the pneumococcus: transmission and evolution. Front Cell Infect Microbiol [Internet]. 2013 Jan [cited 2013 Sep 21];3(March):7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3590460&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationO’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet [Internet]. Elsevier Ltd; 2009 Sep 12 [cited 2013 Aug 27];374(9693):893–902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19748398
dc.source.bibliographicCitationMusher DM. Streptococcus pneumoniae. Principles and Practice of Infectious Diseases [Internet]. Seventh Ed. Elsevier Inc.; 2010. p. 2623–42. Available from: http://dx.doi.org/10.1016/B978-0-443-06839-3.00200-9
dc.source.bibliographicCitationParra EL, Ramos V, Sanabria O, Moreno J. Serotype and Genotype Distribution among Invasive Streptococcus pneumoniae Isolates in Colombia, 2005-2010. PLoS One [Internet]. 2014 Jan [cited 2014 Feb 20];9(1):e84993. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3885649&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationPichichero ME. Otitis media. Pediatr Clin North Am [Internet]. Elsevier Inc; 2013 Apr [cited 2013 Sep 21];60(2):391–407. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23481107
dc.source.bibliographicCitationMusher DM. How effective is vaccination in preventing pneumococcal disease? Infect Dis Clin North Am [Internet]. 2013 Mar [cited 2013 Sep 12];27(1):229–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23398877
dc.source.bibliographicCitationMoffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol [Internet]. Elsevier Ltd; 2011 Jun [cited 2013 Sep 24];23(3):407–13. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3109250&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationJefferies JMC, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin [Internet]. 2011 Oct [cited 2013 Sep 20];7(10):1012–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21941097
dc.source.bibliographicCitationAssaad U, El-Masri I, Porhomayon J, El-Solh A a. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging [Internet]. 2012 Jan;7:453–61. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3496196&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationNunes MC, Madhi SA. Safety, immunogenecity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother. 2012;8(February):161–73.
dc.source.bibliographicCitationCroxtall JD, Keating GM. Pneumococcal Polysaccharide Protein D-Conjugate Vaccine ( Synflorix ; PHiD-CV ). ADIS Drug Profile. 2009;11(5):349–57.
dc.source.bibliographicCitationVesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J [Internet]. 2009 Apr [cited 2013 Sep 27];28(4 Suppl):S66–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19325449
dc.source.bibliographicCitationTasslimi A, Nakamura MM, Levine O, Knoll MD, Russell LB, Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries. Int Health [Internet]. 2011 Dec [cited 2014 Jan 27];3(4):259–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24038499
dc.source.bibliographicCitationStrutton DR, Farkouh R a, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect [Internet]. Elsevier Ltd; 2012 Jan [cited 2014 Jan 27];64(1):54–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22085813
dc.source.bibliographicCitationNational Institute of Allergy and Infectious Diseases. Vaccine Benefits [Internet]. 2014 [cited 2014 May 2]. Available from: http://www.niaid.nih.gov/topics/vaccines/understanding/pages/vaccinebenefits.aspx
dc.source.bibliographicCitationHarvard School of Public Health Study Finds Vaccines Boost the Economies of Poor Countries - October 14, 2005 -2005 Releases - Press Release Archives - Press Releases - Harvard School of Public Health.
dc.source.bibliographicCitationGiglio N, Micone P, Gentile A. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America. Vaccine [Internet]. Elsevier Ltd; 2011 Sep 14 [cited 2013 Sep 6];29 Suppl 3:C35–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21896351
dc.source.bibliographicCitationAkers J, Aguiar-Ibáñez R, Sari AB-A, Beynon S, Booth A, Burch J, et al. Systematic Reviews: CRD’s guidance for undertaking reviews in health care [Internet]. Vasa. York; 2008. Available from: http://medcontent.metapress.com/index/A65RM03P4874243N.pdf
dc.source.bibliographicCitationYeung S, Hansen K, Guinness L. Identifying, measuring and valuing consequences. In: Guinness L, Wiseman V, editors. Introduction to health economics. 2th ed. Berkshire: McGraw-Hill Education; 2011. p. 217–33.
dc.source.bibliographicCitationZweifel P, Breyer F, Kifmann M. Health Economics [Internet]. Second Edi. Vasa. New York: Springer; 2009 [cited 2014 Mar 19]. Available from: http://medcontent.metapress.com/index/A65RM03P4874243N.pdf
dc.source.bibliographicCitationEss SM, Szucs TD. Economic Evaluation of Immunization Strategies. Travel Med. 2002;35(August):294–7.
dc.source.bibliographicCitationArnold RJG. Pharmacoeconomics: From theory to practice. Primera ed. Boca Raton: Taylor & Francis; 2010.
dc.source.bibliographicCitationHiggins J, Green S. Manual Cochrane de revisiones sistemáticas de intervenciones, version 5.1.0. Barcelona: Centro Cochrane Iberoamericano; 2011.
dc.source.bibliographicCitationBorenstein M, Hedged L, Higgings J, Rothstein HR. Introduction to Meta-Analysis. 1st ed. Wiley; 2009.
dc.source.bibliographicCitationMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg [Internet]. 2010 Jan [cited 2013 Sep 4];8(5):336–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20171303
dc.source.bibliographicCitationDrummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic. Br Med J. 1996;313(August):275–83.
dc.source.bibliographicCitationFesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine [Internet]. Elsevier Ltd; 2013 Aug 20 [cited 2013 Sep 12];31(37):3786–804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23830973
dc.source.bibliographicCitationKnerer G., Ismaila A. c, Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: A Markov modelling exercise. J Med Econ [Internet]. 2012;15(1):61–76. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84856048941&partnerID=40&md5=ab0312fbf25329a47e06e6c769ec3643
dc.source.bibliographicCitationNewall AT, Creighton P, Philp DJ, Wood JG, Macintyre CR. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine [Internet]. Elsevier Ltd; 2011;29(45):8077–85. Available from: http://dx.doi.org/10.1016/j.vaccine.2011.08.050
dc.source.bibliographicCitationChuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine [Internet]. Elsevier Ltd; 2010 Jul 26 [cited 2014 Jan 27];28(33):5485–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20554066
dc.source.bibliographicCitationTyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine [Internet]. Elsevier Ltd; 2011 Sep 2 [cited 2014 Jan 27];29(38):6686–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21745516
dc.source.bibliographicCitationEarnshaw SR, McDade CL, Zanotti G, Farkouh R a, Strutton D. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis [Internet]. 2012 Jan;12:101. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3532329&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationTasslimi A., Nakamura MM., Levine O., Knoll MD., Russell LB., Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries. Int Health [Internet]. 2011;3(4):259–69. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84855959564&partnerID=40&md5=bda8ab39373b2cf0776e31e1545dbe41
dc.source.bibliographicCitationNakamura MM, Tasslimi A, Lieu T a, Levine O, Knoll MD, Russell LB, et al. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health [Internet]. Royal Society of Tropical Medicine and Hygiene; 2011 Dec [cited 2013 Sep 21];3(4):270–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24038500
dc.source.bibliographicCitationTalbird SE, Taylor TN, Knoll S, Frostad CR, García Martí S. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine [Internet]. Elsevier Ltd; 2010 Nov 19 [cited 2014 Jan 27];28 Suppl 6:G23–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21075266
dc.source.bibliographicCitationMartí SG, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc [Internet]. 2013 Jan [cited 2014 Jan 27];11(1):21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3766226&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationUrueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine [Internet]. 2011 Jul 12 [cited 2014 Jan 27];29(31):4963–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21621575
dc.source.bibliographicCitationKulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine [Internet]. Elsevier Ltd; 2013 Jun 10 [cited 2013 Sep 12];31(26):2839–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23588084
dc.source.bibliographicCitationMuciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Value Health [Internet]. Elsevier Inc.; 2011 [cited 2014 Jan 27];14(5 Suppl 1):S65–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21839902
dc.source.bibliographicCitationBlank PR, Szucs TD. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine [Internet]. Elsevier Ltd; 2012 Jun 13 [cited 2014 Jan 27];30(28):4267–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22521287
dc.source.bibliographicCitationBoccalini S., Bechini A., Levi M., Tiscione E., Gasparini R., Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccines Immunother [Internet]. 2013;9(3):699–706. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84874677522&partnerID=40&md5=d05b67ce825f6b235c5997fe021c579a
dc.source.bibliographicCitationGomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health [Internet]. BMC Public Health; 2013 Jan [cited 2014 Jan 27];13(1):1025. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24171921
dc.source.bibliographicCitationKim S-Y, Lee G, Goldie SJ. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis [Internet]. 2010 Jan;10:260. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2944347&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationNewall AT, Creighton P, Philp DJ, Wood JG, MacIntyre CR. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine [Internet]. 2011 Oct 19 [cited 2014 Jan 27];29(45):8077–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21864617
dc.source.bibliographicCitationRobberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AKH. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine [Internet]. Elsevier Ltd; 2011 Nov 3 [cited 2014 Jan 27];29(47):8564–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21945264
dc.source.bibliographicCitationTate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine [Internet]. Elsevier Ltd; 2011 Apr 12 [cited 2014 Jan 27];29(17):3329–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21241733
dc.source.bibliographicCitationTürel O, Kisa A, McIntosh EDG, Bakir M. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey. Value Health [Internet]. Elsevier; 2013 [cited 2014 Jan 27];16(5):755–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23947968
dc.source.bibliographicCitationWeycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson L a. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine [Internet]. Elsevier Ltd; 2012 Aug 3 [cited 2014 Jan 27];30(36):5437–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22728289
dc.source.bibliographicCitationChaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A, et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med [Internet]. BioMed Central Ltd; 2011 Jan [cited 2014 Jan 26];9(1):53. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3117724&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationWalker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine [Internet]. Elsevier Ltd; 2010 Mar 8 [cited 2013 Sep 21];28(11):2356–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19567247
dc.source.bibliographicCitationBarbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr Oncol Rep. 2001;3:410–3.
dc.source.bibliographicCitationAkin, Levent, Mehmet Kaya, Serdar Altinel, and Laure Durand. 2011. “Cost of Pneumococcal Infections and Cost-Effectiveness Analysis of Pneumococcal Vaccination at Risk Adults and Elderly in Turkey.” Human Vaccines 7(4): 441–50. http://www.landesbioscience.com/journals/vaccines/article/14188/ (January 27, 2014).
dc.source.bibliographicCitationAyieko, Philip, Ulla K Griffiths, Moses Ndiritu, Jennifer Moisi, Isaac K Mugoya, Tatu Kamau, Mike English, and J Anthony G Scott. 2013. “Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children.” PloS one 8(6): e67324. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3691111&tool=pmcentrez&rendertype=abstract (August 8, 2013).
dc.source.bibliographicCitationBakır, Mustafa, Ozden Türel, and Oleksandr Topachevskyi. 2012. “Cost-Effectiveness of New Pneumococcal Conjugate Vaccines in Turkey: A Decision Analytical Model.” BMC health services research 12: 386. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3529115&tool=pmcentrez&rendertype=abstract (January 27, 2014).
dc.source.bibliographicCitationCastañeda-Orjuela, Carlos, Nelson Alvis-Guzmán, Martha Velandia-González, and Fernando De la Hoz-Restrepo. 2012. “Cost-Effectiveness of Pneumococcal Conjugate Vaccines of 7, 10, and 13 Valences in Colombian Children.” Vaccine 30(11): 1936–43. http://www.ncbi.nlm.nih.gov/pubmed/22266291 (August 8, 2013).
dc.source.bibliographicCitationChaiyakunapruk, Nathorn, Ratchadaporn Somkrua, Raymond Hutubessy, Ana Maria Henao, Joachim Hombach, Alessia Melegaro, John W Edmunds, and Philippe Beutels. 2011. “Cost Effectiveness of Pediatric Pneumococcal Conjugate Vaccines: A Comparative Assessment of Decision-Making Tools.” BMC medicine 9(1): 53. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3117724&tool=pmcentrez&rendertype=abstract (January 26, 2014).
dc.source.bibliographicCitationDíez-Domingo, Javier, Manuel Ridao-López, M Victoria Gutiérrez-Gimeno, Joan Puig-Barberá, Jose a Lluch-Rodrigo, and Eliseo Pastor-Villalba. 2011. “Pharmacoeconomic Assessment of Implementing a Universal PCV-13 Vaccination Programme in the Valencian Public Health System (Spain).” Vaccine 29(52): 9640–48. http://www.ncbi.nlm.nih.gov/pubmed/22027484 (January 27, 2014).
dc.source.bibliographicCitationVan Hoek, A J, Y H Choi, C Trotter, E Miller, and M Jit. 2012. “The Cost-Effectiveness of a 13-Valent Pneumococcal Conjugate Vaccination for Infants in England.” Vaccine 30(50): 7205–13. http://www.scopus.com/inward/record.url?eid=2-s2.0-84869869056&partnerID=40&md5=17a7a7ffbb226901dd42e66c4b652669.
dc.source.bibliographicCitationKlok, Rogier M, Rose-Marie Lindkvist, Mats Ekelund, Raymond a Farkouh, and David R Strutton. 2013. “Cost-Effectiveness of a 10- versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden.” Clinical therapeutics 35(2): 119–34. http://www.ncbi.nlm.nih.gov/pubmed/23312274 (September 16, 2013).
dc.source.bibliographicCitationKnerer, G.a, A.b c Ismaila, and D.d Pearce. 2012. “Health and Economic Impact of PHiD-CV in Canada and the UK: A Markov Modelling Exercise.” Journal of Medical Economics 15(1): 61–76. http://www.scopus.com/inward/record.url?eid=2-s2.0-84856048941&partnerID=40&md5=ab0312fbf25329a47e06e6c769ec3643.
dc.source.bibliographicCitationLee, Kenneth K.C., David Bin Chia Wu, Oleksandr Topachevskyi, Emmanuelle Delgleize, and Rodrigo DeAntonio. 2013. “The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong.” Value in Health Regional Issues 2(1): 64–74. http://linkinghub.elsevier.com/retrieve/pii/S2212109913000137 (January 27, 2014).
dc.source.bibliographicCitationLiguori, Giorgio, Antonino Parlato, Alessandro Sanduzzi Zamparelli, Patrizia Belfiore, Francesca Gallé, Valeria Di Onofrio, Carla Riganti, Bruno Zamparelli, and Società Italiana di Health Horizon Scanning Sihhs. 2013. “Adult Immunization with 13-Valent Pneumococcal Vaccine in Campania Region, South Italy: An Economic Evaluation.” Human vaccines & immunotherapeutics 10(2): 1–6. http://www.ncbi.nlm.nih.gov/pubmed/24185467.
dc.source.bibliographicCitationLiguori, Giorgio, Antonino Parlato, Alessandro Scaletti, and Patrizia Belfiore. 2012. “Opportunities for Prevenar 13 ® Vaccine in Campania Region : A Budget Impact Analysis.” 9(1): 13–19.
dc.source.bibliographicCitationMcGarry, Lisa J, Kristen E Gilmore, Jaime L Rubin, Keith P Klugman, David R Strutton, and Milton C Weinstein. 2013. “Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in a Pandemic Similar to the 2009 H1N1 in the United States.” BMC infectious diseases 13(1): 229. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3668995&tool=pmcentrez&rendertype=abstract (January 27, 2014).
dc.source.bibliographicCitationMerito, M, P Giorgi Rossi, J Mantovani, F Curtale, P Borgia, and G Guasticchi. 2007. “Cost-Effectiveness of Vaccinating for Invasive Pneumococcal Disease in the Elderly in the Lazio Region of Italy.” Vaccine 25(3): 458–65.
dc.source.bibliographicCitationMorano, R, F Perez, M Brosa, and I Perez Escolano. 2011. “[Cost-Effectiveness Analysis of Pneumococcal Vaccination in Spain].” Gac Sanit 25(4): 267–73.
dc.source.bibliographicCitationPradas, R, A Gil de Miguel, A Alvaro, R Gil-Prieto, R Lorente, C Mendez, P Guijarro, and F Antonanzas. 2013. “Budget Impact Analysis of a Pneumococcal Vaccination Programme in the 65-Year-Old Spanish Cohort Using a Dynamic Model.” BMC Infect Dis 13: 175.
dc.source.bibliographicCitationRozenbaum, M H, E Hak, T S van der Werf, and M J Postma. 2010. “Results of a Cohort Model Analysis of the Cost-Effectiveness of Routine Immunization with 13-Valent Pneumococcal Conjugate Vaccine of Those Aged ≥65 Years in the Netherlands.” Clin Ther 32(8): 1517–32. http://www.scopus.com/inward/record.url?eid=2-s2.0-77955915236&partnerID=40&md5=c68c6ca69dc37fba11188645aabbdd5b
dc.source.bibliographicCitationRozenbaum, Mark H, Elisabeth A M Sanders, Albert Jan Van Hoek, Angelique G S C Jansen, Arie Van Der Ende, Gerwin D Rodenburg, and Eelko Hak. 2005. “Cost Effectiveness of Pneumococcal Vaccination among Dutch Infants : An Economic Analysis of the Seven Valent.”
dc.source.bibliographicCitationSartori, Ana Marli Christovam, Patricia Coelho de Soárez, and Hillegonda Maria Dutilh Novaes. 2012. “Cost-Effectiveness of Introducing the 10-Valent Pneumococcal Conjugate Vaccine into the Universal Immunisation of Infants in Brazil.” Journal of epidemiology and community health 66(3): 210–17. http://jech.bmj.com/cgi/content/long/66/3/210 (January 27, 2014).
dc.source.bibliographicCitationSinha, A, D Consienla, J E Valencia, R O’Loughlin, E Gomez, F De La Hoz, M T Valenzuela, and C A De Quadros. 2008. “Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Latin America and the Caribbean: A Regional Analysis.” Revista Panamericana de Salud Publica/Pan American Journal of Public Health 24(5): 304–13. http://www.scopus.com/inward/record.url?eid=2-s2.0-62349097583&partnerID=40&md5=5d66c05dffd81e2564421eb095807482.
dc.source.bibliographicCitationTouray, M M, R Hutubessy, and A Acharya. 2011. “The Cost Effectiveness of Pneumococcal Conjugate Vaccine in the Routine Infant Immunisation Programme of The Gambia.” Journal of Pharmaceutical Health Services Research 2(3): 175–84. http://www.scopus.com/inward/record.url?eid=2-s2.0-80051811740&partnerID=40&md5=0c9fe22140ac889b3b2456ec4da06e5c.
dc.source.bibliographicCitationVespa, G, D O Constenla, C Pepe, M A Safadi, E Berezin, J C de Moraes, C A de Campos, D V Araujo, and A L de Andrade. 2009. “Estimating the Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Brazil.” Rev Panam Salud Publica 26(6): 518–28.
dc.source.bibliographicCitationDe Wals, Philippe, Steven Black, Ray Borrow, and David Pearce. 2009. “Modeling the Impact of a New Vaccine on Pneumococcal and Nontypable Haemophilus Influenzae Diseases: A New Simulation Model.” Clinical therapeutics 31(10): 2152–69. http://www.ncbi.nlm.nih.gov/pubmed/19922887 (January 27, 2014).
dc.source.bibliographicCitationWu, David Bin-Chia, Chee-Jen Chang, Yu-Chering Huang, Yu-Wen Wen, Chia-Ling Wu, and Cathy Shen-Jang Fann. 2012. “Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccine in Taiwan: A Transmission Dynamic Modeling Approach.” Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 15(1 Suppl): S15–9. http://www.ncbi.nlm.nih.gov/pubmed/22265061 (January 27, 2014).
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

 

Reconocimientos: